scholarly article | Q13442814 |
P50 | author | Niraj H Tolia | Q55175593 |
Dhelio Batista Pereira | Q56543847 | ||
Francis Ntumngia | Q63639200 | ||
Samantha J Barnes | Q89705262 | ||
Luzia Helena Carvalho | Q90459284 | ||
Camilla Pires de Souza | Q96212716 | ||
Richard Thomson-Luque | Q101237597 | ||
Miriam T George | Q114412168 | ||
Flora S Kano | Q114412170 | ||
John H. Adams | Q47150509 | ||
P2093 | author name string | Christopher L King | |
Darya Urusova | |||
Jessica R S Alves | |||
P2860 | cites work | Vivax malaria in Mauritania includes infection of a Duffy-negative individual | Q21034116 |
Red blood cell invasion by Plasmodium vivax: structural basis for DBP engagement of DARC | Q21131367 | ||
The Resistance Factor to Plasmodium vivax in Blacks | Q22250916 | ||
Plasmodium vivax clinical malaria is commonly observed in Duffy-negative Malagasy people | Q24600330 | ||
Diversity and natural selection in Plasmodium vivax Duffy binding protein gene | Q56379448 | ||
HIV-1 vaccine candidate ineffective | Q56907412 | ||
Vaccine development strategies for improving immunization: the role of modern immunology | Q80020558 | ||
Immune effector mechanisms in malaria | Q82383609 | ||
Increasing the potency and breadth of an HIV antibody by using structure-based rational design | Q24631510 | ||
In vitro evaluation of the role of the Duffy blood group in erythrocyte invasion by Plasmodium vivax | Q24681976 | ||
Dimerization of Plasmodium vivax DBP is induced upon receptor binding and drives recognition of DARC | Q27670749 | ||
The March Toward Malaria Vaccines | Q28084325 | ||
Plasmodium vivax invasion of human erythrocytes inhibited by antibodies directed against the Duffy binding protein | Q28471832 | ||
Structural analysis of the synthetic Duffy Binding Protein (DBP) antigen DEKnull relevant for Plasmodium vivax malaria vaccine design | Q28544738 | ||
Positive Darwinian evolution in human influenza A viruses | Q28775815 | ||
The neglected burden of Plasmodium vivax malaria | Q29618450 | ||
Vivax malaria: neglected and not benign | Q29619167 | ||
Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1 | Q29619511 | ||
A family of erythrocyte binding proteins of malaria parasites | Q33198214 | ||
Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: results of a phase I randomized trial | Q33264523 | ||
Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea | Q33344896 | ||
Severe Plasmodium vivax malaria: a report on serial cases from Bikaner in northwestern India | Q33383089 | ||
Mapping epitopes of the Plasmodium vivax Duffy binding protein with naturally acquired inhibitory antibodies | Q33676028 | ||
Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge | Q33804531 | ||
Determination of the molecular basis for a limited dimorphism, N417K, in the Plasmodium vivax Duffy-binding protein | Q33918156 | ||
Naturally acquired and vaccine-elicited antibodies block erythrocyte cytoadherence of the Plasmodium vivax Duffy binding protein. | Q34004570 | ||
Immunogenicity of a synthetic vaccine based on Plasmodium vivax Duffy binding protein region II. | Q34260750 | ||
Allelic diversity and naturally acquired allele-specific antibody responses to Plasmodium falciparum apical membrane antigen 1 in Kenya | Q34290806 | ||
Identification of the erythrocyte binding domains of Plasmodium vivax and Plasmodium knowlesi proteins involved in erythrocyte invasion | Q34331219 | ||
Natural variation within the principal adhesion domain of the Plasmodium vivax duffy binding protein | Q34548865 | ||
Evidence for transmission of Plasmodium vivax among a duffy antigen negative population in Western Kenya. | Q34573683 | ||
Plasmodium vivax infection among Duffy antigen-negative individuals from the Brazilian Amazon region: an exception? | Q34644273 | ||
Design and immunogenicity of a novel synthetic antigen based on the ligand domain of the Plasmodium vivax duffy binding protein | Q35666191 | ||
Severe Plasmodium vivax malaria, Brazilian Amazon | Q35804562 | ||
Conserved and variant epitopes of Plasmodium vivax Duffy binding protein as targets of inhibitory monoclonal antibodies | Q35805433 | ||
Targeting a Neutralizing Epitope of HIV Envelope Gp120 by Immune Complex Vaccine | Q36157711 | ||
A reliable ex vivo invasion assay of human reticulocytes by Plasmodium vivax | Q36225497 | ||
The domain on the Duffy blood group antigen for binding Plasmodium vivax and P. knowlesi malarial parasites to erythrocytes | Q36367429 | ||
Immune responses to asexual blood-stages of malaria parasites | Q36412872 | ||
Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection | Q36751523 | ||
Role of Plasmodium vivax Duffy-binding protein 1 in invasion of Duffy-null Africans | Q36978062 | ||
Broadly neutralizing epitopes in the Plasmodium vivax vaccine candidate Duffy Binding Protein | Q36978206 | ||
Toward an AIDS vaccine | Q37158259 | ||
A Novel Erythrocyte Binding Protein of Plasmodium vivax Suggests an Alternate Invasion Pathway into Duffy-Positive Reticulocytes | Q37208395 | ||
Strain-specific duffy binding protein antibodies correlate with protection against infection with homologous compared to heterologous plasmodium vivax strains in Papua New Guinean children | Q37333369 | ||
Conserved residues in the Plasmodium vivax Duffy-binding protein ligand domain are critical for erythrocyte receptor recognition | Q37595658 | ||
Structural basis of immune recognition of influenza virus hemagglutinin | Q37925554 | ||
Malaria vaccines and human immune responses | Q38854831 | ||
Primaquine resistance in Plasmodium vivax | Q38950998 | ||
Immunogenicity of single versus mixed allele vaccines of Plasmodium vivax Duffy binding protein region II. | Q39115271 | ||
Plasmodium falciparum merozoite surface protein 3 is a target of allele-specific immunity and alleles are maintained by natural selection | Q39362543 | ||
Strong diversifying selection on domains of the Plasmodium falciparum apical membrane antigen 1 gene | Q39362584 | ||
Epitope-specific humoral immunity to Plasmodium vivax Duffy binding protein. | Q39746136 | ||
Immune Responses in Malaria | Q40259888 | ||
Congenital malaria due to chloroquine-resistant Plasmodium vivax: a case report | Q40361430 | ||
Plasmodium vivax:a glimpse into the unique and shared biology of the merozoite | Q40441210 | ||
Antigenic drift in the ligand domain of Plasmodium vivax duffy binding protein confers resistance to inhibitory antibodies | Q45062896 | ||
Sulphated tyrosines mediate association of chemokines and Plasmodium vivax Duffy binding protein with the Duffy antigen/receptor for chemokines (DARC). | Q45273570 | ||
Mapping binding residues in the Plasmodium vivax domain that binds Duffy antigen during red cell invasion | Q45273574 | ||
Naturally acquired inhibitory antibodies to Plasmodium vivax Duffy binding protein are short-lived and allele-specific following a single malaria infection | Q47812027 | ||
Inhibitory properties of the antibody response to Plasmodium vivax Duffy binding protein in an area with unstable malaria transmission | Q47858810 | ||
Allelic polymorphisms in apical membrane antigen-1 are responsible for evasion of antibody-mediated inhibition in Plasmodium falciparum | Q47864459 | ||
The erythrocyte binding motif of plasmodium vivax duffy binding protein is highly polymorphic and functionally conserved in isolates from Papua New Guinea | Q47876528 | ||
Biochemical, biophysical, and functional characterization of bacterially expressed and refolded receptor binding domain of Plasmodium vivax duffy-binding protein | Q47880785 | ||
Age-dependent cellular immune responses to Plasmodium vivax Duffy binding protein in humans | Q47911727 | ||
Anti-Plasmodium vivax duffy binding protein antibodies measure exposure to malaria in the Brazilian Amazon. | Q48010530 | ||
Genetic polymorphism of the Duffy receptor binding domain of Plasmodium vivax in Colombian wild isolates | Q48031812 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Plasmodium vivax | Q311376 |
P304 | page(s) | 13779 | |
P577 | publication date | 2017-10-23 | |
P1433 | published in | Scientific Reports | Q2261792 |
P1476 | title | An engineered vaccine of the Plasmodium vivax Duffy binding protein enhances induction of broadly neutralizing antibodies | |
P478 | volume | 7 |
Q59129806 | Blood-stage Plasmodium vivax antibody dynamics in a low transmission setting: A nine year follow-up study in the Amazon region |
Q94606197 | Dynamics of IgM and IgG responses to the next generation of engineered Duffy binding protein II immunogen: Strain-specific and strain-transcending immune responses over a nine-year period |
Q92827824 | Identification and Characterization of Functional Human Monoclonal Antibodies to Plasmodium vivax Duffy-Binding Protein |
Q64054791 | Identification of an Immunogenic Broadly Inhibitory Surface Epitope of the Plasmodium vivax Duffy Binding Protein Ligand Domain |
Q56340290 | Immunization with Recombinant Plasmodium falciparum Erythrocyte Membrane Protein 1 CIDRα1 Domains Induces Domain Subtype Inhibitory Antibodies. |
Q58754493 | On the Evolution and Function of Reticulocyte Binding Surface Antigen () |
Q55429433 | Structural patterns of selection and diversity for Plasmodium vivax antigens DBP and AMA1. |